Guide

21 CFR 606 cGMP: A Practical Readiness Guide for Licensed Blood Establishments

21 CFR Part 606 sets Current Good Manufacturing Practice for blood and blood components in the United States — collection, processing, storage, compatibility testing, distribution and the Biological Product Deviation Report (BPDR) at §606.171. It sits over Part 600 (licensure), Part 610 (general biological product standards) and Part 630 (donor eligibility), and under it sit the AABB Standards as the practical implementation overlay for most US blood centres. This guide walks the integrated 600/606/610/630 framework, the recurring FDA inspection findings, and a practical path to a defensible licensed blood establishment.

Start free trial Free trial, no credit card, onboard in days, not months.

Licensure vs registration and what 606 actually requires

Blood establishments that ship blood or components in interstate commerce must hold a biologics licence (BLA) under Part 600 unless an exception applies; hospital transfusion services and intrastate operations register and operate under 606/610/630 without a BLA. Part 606 sets the cGMP overlay — organisation and personnel (606.20), facilities (606.40), equipment (606.60), supplies and reagents (606.65), standard operating procedures (606.100), records (606.160) and BPDR (606.171). FDA inspects against 606 regardless of AABB accreditation status.

Donor eligibility under 21 CFR 630 and the 2024–2026 refresh

Part 630 sets donor eligibility — registration, identification, medical history, physical, deferral and look-back. The framework has been refreshed substantially across 2024–2026 including the HIV individual risk assessment replacing time-based deferral. A donor eligibility programme that has not been re-validated against the current Part 630 and the linked guidance is a routine inspection finding. The determination itself — not the test results in isolation — is what the inspector reads.

Component preparation, labelling and ISBT 128

606.121 sets labelling requirements and ISBT 128 is the practical implementation standard. The recurring finding is an ISBT 128 implementation that handles the data block correctly but breaks down on linkage — the label says one thing, the donor file says another, or the transfusion record cannot be traced back without a manual search. 606.160 requires records that permit tracing of any unit from source to disposition.

The BPDR at §606.171 and the 45-day clock

Biological Product Deviation Reports are required for events that may affect safety, purity or potency of a distributed product, filed on Form 3486 within 45 calendar days of discovery. Recurring findings: under-reporting (events held in deviation log without 606.171 evaluation), late filing (clock started at root cause meeting rather than discovery), and incomplete investigation (report filed but investigation file thin). The investigation is the deliverable to the inspector; the form is the deliverable to FDA.

A 60-day readiness path

Days 1–10: licensure and scope check (600 vs 606-only). Days 11–25: donor eligibility refresh against current Part 630 and 2024–2026 guidance. Days 26–40: ISBT 128 implementation audit with linkage focus. Days 41–50: BPDR clock-discipline and 606.171 evaluation workflow review; rehearse a real case. Days 51–60: integrated 606/AABB internal audit, management review and inspection readiness rehearsal.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

21 CFR 606

The FDA cGMP rule for blood centers and transfusion services — personnel, facilities, equipment, supplies, process controls, labelling, lab controls, records, and biological product deviation reporting.

ISBT 128

The global standard for identification, coding, and labelling of Medical Products of Human Origin — blood components, cellular therapy products, tissue allografts, ocular tissue, and donor milk.

Donor eligibility

The formal, documented determination — risk assessment plus IDM testing — that a donor's blood or tissue donation may be released for clinical use.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

Blood establishment QMS

606 + AABB on one configuration.

BPDR (Form 3486)

45-day clock from discovery, not from root cause.

ISBT 128 labelling

Label, donor file and transfusion record linked.

Industries this hits hardest

Blood & tissue

Frequently asked

Do we need a BLA to operate?

Only if you ship blood or components in interstate commerce, with limited exceptions. Hospital transfusion services and many intrastate operations register and operate under 606/610/630 without a BLA. The cGMP requirements at 606 apply either way.

How does 606 relate to AABB Standards?

606 is the legal floor; AABB Standards are the practical implementation overlay used by most US blood centres and typically set the bar higher. A compliant programme implements the higher of the two where they diverge.

What is the difference between a BPDR (606.171) and a fatality report (606.170)?

Fatality reports under 606.170 are filed within 24 hours by telephone/email when a fatality may be related to blood collection or transfusion. BPDRs under 606.171 are filed on Form 3486 within 45 calendar days for deviations affecting safety, purity or potency. The two regimes are independent and both can apply to the same event.

How long must blood establishment records be retained?

606.160(d) requires retention for at least 10 years after the records are created or 6 months after the latest expiration of the unit, whichever is later. Indefinite retention applies to certain donor records under 610.46/47 look-back requirements.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →